You are here

Coronavirus (COVID-19): Information on medicines and medical devices

The TGA is publishing the latest information about medicines and medical devices as it relates to COVID-19 on this page.

Please read the information below before contacting the TGA to see if your question is already answered.

24 March 2021

Information about the post-market review of all approved COVID-19 tests and a post-market evaluation of all approved serology-based COVID point-of-care tests.

11 March 2021
In response to the COVID-19 pandemic, the TGA has expedited the approval (with conditions) of COVID-19 tests including tests intended for laboratory use and those intended for use by specified health professionals at the point of care.
10 March 2021
Information about the TGA's safety monitoring of COVID-19 vaccines
3 March 2021
Information about the TGA's safety monitoring of COVID-19 vaccines
16 February 2021
The TGA has granted provisional approval to AstraZeneca Pty Ltd for its COVID-19 vaccine
9 February 2021
A comprehensive system is in place to capture reports of adverse events following COVID-19 vaccination.
9 February 2021

The plan outlines five key strategies to strengthen Australia's vaccine vigilance system.

9 February 2021

Access the COVID-19 vaccine weekly safety report, and learn how the TGA continues to monitor the safety of vaccines so that we can detect and respond to any safety concerns

8 February 2021
Australia, through the TGA, is one of only five non-European Union regulators formally invited to participate by the European Medicines Agency (EMA)
2 February 2021
The TGA has concluded that there is no specific risk of vaccination with the Pfizer-BioNTech COVID-19 vaccine in elderly patients.

Pages

Further information

Contact TGA Info

Tel: 1800 020 653
Email: info@tga.gov.au

Note: we are currently experiencing a high volume of calls and emails. Please bear with us as we try to respond to queries as quickly as possible.

Department of Health

Coronavirus (COVID-19) health alert — for information and advice not specific to therapeutic goods.

Follow us